Inmaculada Hernandez (HPM ’16) is assistant professor in the Pitt School of Pharmacy. She earned her PharmD degree and a master's in health economics in Spain and completed her PhD at Pitt Public Health in three years. She has earned multiple academic awards as she continues her career in the health services of pharmaceutical polices, culminating in being named one of Forbes magazine’s 30 Under 30 in Healthcare in 2019.
HEALIO - During a shortage, drug prices increase two times as quickly as they would have in the absence of a shortage, according to findings published in Annals of Internal Medicine. “Prescription drug shortages may result in substitution of less effective drugs, delays in necessary treatments, and omission of or reductions in doses,” INMACULADA HERNANDEZ (HPM '16) and colleagues wrote.
POLITICO - The payment deal for Kymriah therapy drew internal HHS scrutiny and is the target of current congressional investigations of Swiss drug giant Novartis. The company's pivotal study of the drug's in children with acute lymphoblastic leukemia found that at one year, about one out of every three patients the government would be covering would get sick again, said INMACULADA HERNANDEZ (HPM '16).
ASPPH FRIDAY LETTER - In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients. "Having multiple prescribers who are not in communication increases the risk for overdose,” says HPM's YUTING ZHANG. "Policy interventions should focus on preventing concurrent exposure,” says INMACULADA HERNANDEZ (HPM '16).
JOHANNA BELLON (HPM '15) is the Senior Director of Quality Analytics and Performance at the UPMC Wolff Center. UPMC is a 40+ hospital integrated finance and delivery system with over 3,500 providers and a multitude of clinical sites.
INMACULADA HERNANDEZ (HPM ‘16) is working on developing her own independent research program at Pitt's School of Pharmacy, which is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics and pharmaceutical policy.
More Pitt Public Health News
TRI LE (HPM '16) is currently a research analyst in the Quality Measurement and Health Policy program at RTI International. He is part of a team that develops, maintains, re-evaluates, and implements outcome, structural, process, and composite quality measures for the Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNFs), and nursing home post-acute care quality programs.